FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015174103> ?p ?o ?g. }

• W2015174103 endingPage "1396" @default.
• W2015174103 startingPage "1388" @default.
• W2015174103 abstract "The potential consequences of an avian influenza pandemic warrants the development of safe, highly immunogenic pre-pandemic A/H5N1 vaccines with cross-clade protection. In this randomized, controlled study we compared the immunogenicity and safety of an MF59(®)-adjuvanted (Novartis Vaccines, Marburg, Germany) A/H5N1 pre-pandemic vaccine with that of a licensed, MF59-adjuvanted, seasonal influenza vaccine.Healthy adult (18-60 years, n=3372) and elderly (≥61 years, n=275) volunteers received either an initial dose of a licensed, non-adjuvanted, trivalent, seasonal influenza vaccine (Agrippal(®)) on Day 1, followed by one dose of MF59-H5N1 study vaccine on Day 22 and a second dose of MF59-H5N1 on Day 43, or alternatively, placebo on Day 1 followed by one dose of MF59-adjuvanted seasonal reference vaccine on Day 22 and a second dose of reference vaccine on Day 43. Homologous and cross-reactive A/H5N1 antibody responses were analysed by haemagglutination inhibition (HI), single radial haemolysis (SRH), and microneutralization (MN) assays three weeks after each vaccination. Vaccine safety was assessed throughout the study.Analysis by HI assay found that two doses of MF59-H5N1 resulted in a seroconversion rate of 56% and a geometric mean ratio (GMR) of 7.1 in adult subjects. Similar results were observed on analysis by SRH (GMR 4.03; seroconversion 78% and seroprotection 91%) and MN (seroconversion 67%) assays. These data met the European licensure criteria for influenza vaccines. No significant difference in immunogenicity was detected between the adult and elderly populations. Anti-A/H5N1 cross-clade antibodies were detected by SRH, 49% of adult and 32% of elderly subjects achieved seroconversion after the second vaccine dose. Overall, MF59-H5N1 containing 7.5μg antigen was less reactogenic than the MF59-adjuvanted trivalent seasonal vaccine which contained 15μg antigen for each component strain.Two doses of MF59-H5N1 vaccine were well tolerated and induced adequate levels of seroprotection against homologous and cross-clade A/H5N1 virus. These data support the suitability of MF59-adjuvanted A/H5N1 vaccine for pre-pandemic use in adults and the elderly." @default.
• W2015174103 created "2016-06-24" @default.
• W2015174103 creator A5002010440 @default.
• W2015174103 creator A5008146631 @default.
• W2015174103 creator A5012683569 @default.
• W2015174103 creator A5014368319 @default.
• W2015174103 creator A5022249393 @default.
• W2015174103 creator A5047153448 @default.
• W2015174103 creator A5061270482 @default.
• W2015174103 creator A5063861111 @default.
• W2015174103 creator A5070167207 @default.
• W2015174103 date "2012-02-01" @default.
• W2015174103 modified "2023-10-18" @default.
• W2015174103 title "Safety and immunogenicity of an MF59®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly" @default.
• W2015174103 cites W1965755102 @default.
• W2015174103 cites W1976670588 @default.
• W2015174103 cites W1977593306 @default.
• W2015174103 cites W1984346378 @default.
• W2015174103 cites W2006219611 @default.
• W2015174103 cites W2024103022 @default.
• W2015174103 cites W2024412478 @default.
• W2015174103 cites W2036596307 @default.
• W2015174103 cites W2037409337 @default.
• W2015174103 cites W2038964902 @default.
• W2015174103 cites W2047574261 @default.
• W2015174103 cites W2048092342 @default.
• W2015174103 cites W2052066860 @default.
• W2015174103 cites W2055984914 @default.
• W2015174103 cites W2057647944 @default.
• W2015174103 cites W2067830747 @default.
• W2015174103 cites W2070003896 @default.
• W2015174103 cites W2078394827 @default.
• W2015174103 cites W2084449201 @default.
• W2015174103 cites W2087508560 @default.
• W2015174103 cites W2090540879 @default.
• W2015174103 cites W2092240421 @default.
• W2015174103 cites W2093051020 @default.
• W2015174103 cites W2103758376 @default.
• W2015174103 cites W2107487305 @default.
• W2015174103 cites W2130490068 @default.
• W2015174103 cites W2131170401 @default.
• W2015174103 cites W2139730049 @default.
• W2015174103 cites W2139738904 @default.
• W2015174103 cites W2144894027 @default.
• W2015174103 cites W2158299279 @default.
• W2015174103 cites W2162235679 @default.
• W2015174103 cites W2163192885 @default.
• W2015174103 cites W279343580 @default.
• W2015174103 doi "https://doi.org/10.1016/j.vaccine.2011.12.009" @default.
• W2015174103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22192847" @default.
• W2015174103 hasPublicationYear "2012" @default.
• W2015174103 type Work @default.
• W2015174103 sameAs 2015174103 @default.
• W2015174103 citedByCount "51" @default.
• W2015174103 countsByYear W20151741032012 @default.
• W2015174103 countsByYear W20151741032013 @default.
• W2015174103 countsByYear W20151741032014 @default.
• W2015174103 countsByYear W20151741032015 @default.
• W2015174103 countsByYear W20151741032016 @default.
• W2015174103 countsByYear W20151741032017 @default.
• W2015174103 countsByYear W20151741032018 @default.
• W2015174103 countsByYear W20151741032019 @default.
• W2015174103 countsByYear W20151741032020 @default.
• W2015174103 countsByYear W20151741032021 @default.
• W2015174103 countsByYear W20151741032022 @default.
• W2015174103 countsByYear W20151741032023 @default.
• W2015174103 crossrefType "journal-article" @default.
• W2015174103 hasAuthorship W2015174103A5002010440 @default.
• W2015174103 hasAuthorship W2015174103A5008146631 @default.
• W2015174103 hasAuthorship W2015174103A5012683569 @default.
• W2015174103 hasAuthorship W2015174103A5014368319 @default.
• W2015174103 hasAuthorship W2015174103A5022249393 @default.
• W2015174103 hasAuthorship W2015174103A5047153448 @default.
• W2015174103 hasAuthorship W2015174103A5061270482 @default.
• W2015174103 hasAuthorship W2015174103A5063861111 @default.
• W2015174103 hasAuthorship W2015174103A5070167207 @default.
• W2015174103 hasConcept C126322002 @default.
• W2015174103 hasConcept C133239900 @default.
• W2015174103 hasConcept C159047783 @default.
• W2015174103 hasConcept C159654299 @default.
• W2015174103 hasConcept C203014093 @default.
• W2015174103 hasConcept C22070199 @default.
• W2015174103 hasConcept C2522874641 @default.
• W2015174103 hasConcept C2777451964 @default.
• W2015174103 hasConcept C2777546802 @default.
• W2015174103 hasConcept C2779134260 @default.
• W2015174103 hasConcept C2780689484 @default.
• W2015174103 hasConcept C2780868878 @default.
• W2015174103 hasConcept C3008058167 @default.
• W2015174103 hasConcept C519248777 @default.
• W2015174103 hasConcept C524204448 @default.
• W2015174103 hasConcept C71924100 @default.
• W2015174103 hasConcept C89623803 @default.
• W2015174103 hasConceptScore W2015174103C126322002 @default.
• W2015174103 hasConceptScore W2015174103C133239900 @default.
• W2015174103 hasConceptScore W2015174103C159047783 @default.
• W2015174103 hasConceptScore W2015174103C159654299 @default.
• W2015174103 hasConceptScore W2015174103C203014093 @default.

• next